Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Robert James Glynn, Sc.D., Ph.D.

Co-Author

This page shows the publications co-authored by Robert Glynn and Peter Libby.
Connection Strength

1.382
  1. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J. 2018 10 07; 39(38):3499-3507.
    View in: PubMed
    Score: 0.201
  2. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012 Aug 11; 380(9841):565-71.
    View in: PubMed
    Score: 0.131
  3. Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Am J Cardiol. 2010 Jul 15; 106(2):204-9.
    View in: PubMed
    Score: 0.113
  4. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009 Apr 30; 360(18):1851-61.
    View in: PubMed
    Score: 0.104
  5. The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials. Eur Heart J. 2021 03 01; 42(9):896-903.
    View in: PubMed
    Score: 0.059
  6. Inhibition of Interleukin-1ß and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial. J Am Coll Cardiol. 2020 10 06; 76(14):1660-1670.
    View in: PubMed
    Score: 0.058
  7. Effects of Interleukin-1ß Inhibition on Incident Anemia: Exploratory Analyses From a Randomized Trial. Ann Intern Med. 2020 04 21; 172(8):523-532.
    View in: PubMed
    Score: 0.056
  8. Effects of Interleukin-1ß Inhibition on Blood Pressure, Incident Hypertension, and Residual Inflammatory Risk: A Secondary Analysis of CANTOS. Hypertension. 2020 02; 75(2):477-482.
    View in: PubMed
    Score: 0.055
  9. Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure. Circulation. 2019 03 05; 139(10):1289-1299.
    View in: PubMed
    Score: 0.052
  10. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. N Engl J Med. 2019 02 21; 380(8):752-762.
    View in: PubMed
    Score: 0.051
  11. Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. Am Heart J. 2018 12; 206:80-93.
    View in: PubMed
    Score: 0.050
  12. Relationship of Interleukin-1ß Blockade With Incident Gout and Serum Uric Acid Levels: Exploratory Analysis of a Randomized Controlled Trial. Ann Intern Med. 2018 10 16; 169(8):535-542.
    View in: PubMed
    Score: 0.050
  13. Inhibition of Interleukin-1ß by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease. J Am Coll Cardiol. 2018 05 29; 71(21):2405-2414.
    View in: PubMed
    Score: 0.049
  14. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. J Am Coll Cardiol. 2018 05 29; 71(21):2392-2401.
    View in: PubMed
    Score: 0.048
  15. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018 01 27; 391(10118):319-328.
    View in: PubMed
    Score: 0.047
  16. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017 09 21; 377(12):1119-1131.
    View in: PubMed
    Score: 0.047
  17. Effect of interleukin-1ß inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017 Oct 21; 390(10105):1833-1842.
    View in: PubMed
    Score: 0.047
  18. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J. 2013 Aug; 166(2):199-207.e15.
    View in: PubMed
    Score: 0.035
  19. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet. 2010 Jul 31; 376(9738):333-9.
    View in: PubMed
    Score: 0.028
  20. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circ Cardiovasc Qual Outcomes. 2009 Nov; 2(6):616-23.
    View in: PubMed
    Score: 0.027
  21. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009 Apr 04; 373(9670):1175-82.
    View in: PubMed
    Score: 0.026
  22. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 Nov 20; 359(21):2195-207.
    View in: PubMed
    Score: 0.025
  23. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Am J Cardiol. 2007 Dec 01; 100(11):1659-64.
    View in: PubMed
    Score: 0.024
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.